Table 2.
Biologic therapy during pregnancy in women with inflammatory bowel disease and risk of major types of infantile infections
| Study | Year | Biologic therapy | Acute otitis media | Upper respiratory infection infections | Urinary tract infections | Gastrointestinal infections |
|---|---|---|---|---|---|---|
| de Lima etal. (21) | 2016 | IFX, ADA | 1 | 5 | 0 | 0 |
| Control (no anti-TNF) | 19 | 13 | 0 | 1 | ||
| Moens etal. (22) | 2019 | VDZ | 0 | 0 | 1 | 0 |
| IFX, ADA | 1 | 2 | 1 | 0 | ||
| Control (no biologic) | 0 | 0 | 0 | 0 | ||
| Duricova etal. (23) | 2018 | IFX, ADA | 1 | 9 | 5 | 1 |
| Control (no anti-TNF) | 1 | 3 | 4 | 0 | ||
| Casanova etal. (24) | 2013 | IFX, ADA, CTZ | No data | No data | No data | No data |
| Control (no anti-TNF) | No data | No data | No data | No data | ||
| Seirafi etal. (25) | 2014 | IFX, ADA, CTZ | 0 | 2 | 0 | 0 |
| Control (no anti-TNF) | 0 | 1 | 0 | 0 | ||
| Luu et al. (14) | 2018 | IFX, ADA, CTZ, GOL | 19 | 7 | 7 | 12 |
| Control (no anti-TNF) | 54 | 31 | 31 | 56 | ||
| Soares etal. (26) | 2016 | IFX, ADA | No data | No data | No data | No data |
| Control (no anti-TNF) | No data | No data | No data | No data | ||
| Chaparro etal. (27) | 2018 | IFX, ADA, CTZ | 2 | 22 | 7 | 6 |
| Control (no anti-TNF) | 3 | 24 | 3 | 6 | ||
| Matro etal. (28) | 2018 | IFX, ADA, CTZ, GOL, NAT, UST | 46 | No data | No data | No data |
| Control (no anti-TNF) | 48 | No data | No data | No data |
ADA, adalimumab; CTZ, certolizumab; GOL, golimumab; IFX, infliximab; NAT, natalizumab; TNF, tumor necrosis factor; UST, ustekinumab; VDZ, vedolizumab.